Catalog No.
Product Name
Application
Product Information
Citations
-
Anti-inflammatory/Antiinfection Agent
Forsyshiyanine A is a triterpenoid alkaloid known for its anti-inflammatory and antiviral properties. It effectively inhibits the release of β-glucuronidase from rat polymorphonuclear leukocytes, thereby demonstrating notable anti-inflammatory activity. Forsyshiyanine A also exhibits antiviral efficacy, with an EC50 of 4.5 μM against respiratory syncytial virus (RSV) and an IC50 of 7.3 μM against influenza A virus (H1N1), reducing viral load through disruption of viral replication and entry. This compound is valuable for research in the fields of inflammation and infection. -
Bioactive Peptide
Influenza NP (311-325) is a bioactive peptide derived from the nucleoprotein (NP) of the influenza virus, acting as an MHC class II restricted epitope to stimulate host immune responses. This peptide is known for its ability to induce substantial interferon gamma (IFN-γ) production while avoiding activation of CD8 T cells in murine models. Its unique properties make Influenza NP (311-325) a valuable tool for research in immunology and vaccine development. -
Anti-Inflammatory Agent
Agathisflavone is a flavonoid compound primarily recognized for its anti-inflammatory properties. It exhibits a range of biological activities, including antioxidant, antiviral, antiparasitic, cytotoxic, neuroprotective, and hepatoprotective effects. Research indicates that Agathisflavone may enhance tissue repair processes, particularly in spinal cord injury models in rodents, making it a valuable reagent for studies in inflammation and regenerative medicine. -
Nonimmunosuppressive Cyclophilin Inhibitor
NIM258 is a potent nonimmunosuppressive cyclophilin inhibitor, specifically targeting cyclophilin A with a Kd of 1.2 nM. It exhibits significant anti-HCV activity, with an EC50 of 40 nM. This compound serves as a valuable tool for research into HCV infection and its associated pathways. -
CXCR4 Antagonist
Mavorixafor trihydrochloride is a potent and selective antagonist of the CXCR4 receptor, exhibiting an IC50 of 13 nM in inhibiting CXCR4 125I-SDF binding. This compound has demonstrated significant antiviral activity by inhibiting the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs, with IC50 values of 1 nM and 9 nM, respectively. Mavorixafor trihydrochloride is applicable in research studying WHIM syndrome and various CXCR4-related biological processes. -
CCR7 and CXCR2 Antagonist
Cosalane is a dual antagonist of the chemokine receptors CCR7 (IC50 = 2.43 μM) and CXCR2 (IC50 = 0.66 μM). This compound effectively inhibits HIV replication across a variety of strains, including HIV-1, HIV-2, Rauscher murine leukemia virus, as well as herpes simplex viruses HSV-1 and HSV-2, and human cytomegalovirus. Cosalane disrupts the interaction between gp120 and CD4, inhibiting signaling downstream of CCR7 in response to its ligands CCL19 and CCL21. Research applications include studies on HIV and the potential modulation of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. -
CCR5 Inhibitor
DAPTA is a synthetic peptide that acts as a selective inhibitor of the CCR5 receptor. By blocking CCR5, DAPTA interferes with viral entry into host cells, exhibiting significant anti-HIV activity. This compound is valuable for research in virology and the development of therapeutic strategies against HIV. -
CXCR4 Antagonist
TC14012 is a peptidomimetic antagonist targeting the chemokine receptor CXCR4, exhibiting a high level of selectivity with an IC50 of 19.3 nM. In addition, TC14012 acts as a potent agonist for CXCR7, demonstrating an EC50 of 350 nM in β-arrestin 2 recruitment assays. This compound is utilized in research focused on HIV and cancer therapy, showcasing its potential in modulating chemokine signaling pathways. -
CXCR4 Antagonist
FC131 TFA is a potent CXCR4 antagonist that effectively inhibits the binding of [125I]-SDF-1 to CXCR4, demonstrating an IC50 value of 4.5 nM. This compound exhibits significant anti-HIV activity, making it a valuable tool for research in HIV treatment and other CXCR4-related studies. Its ability to disrupt CXCR4 signaling can be explored in various biological contexts, including cancer metastasis and immune response regulation. -
CXCR4 Antagonist
AMD 3465 is a potent antagonist of the CXCR4 chemokine receptor. It effectively inhibits the binding of both the 12G5 monoclonal antibody and CXCL12AF647 to CXCR4, demonstrating IC50 values of 0.75 nM and 18 nM in SupT1 cells, respectively. Additionally, AMD 3465 significantly impedes the replication of X4-tropic HIV strains, with IC50 values ranging from 1 to 10 nM, while showing no activity against CCR5-using (R5) viruses. This compound is suitable for research applications focusing on HIV treatment and CXCR4-related signaling pathways. -
CCR5 Antagonist
Aplaviroc hydrochloride is a potent CCR5 antagonist targeting the CCR5 co-receptor. It demonstrates biological activity with IC50 values ranging from 0.1 to 0.4 nM against various HIV-1 strains, including HIV-1Ba-L, HIV-1JRFL, and HIV-1MOKW. This compound is valuable for research applications focused on HIV entry inhibition and the development of antiviral therapies. -
HIV-1 Nef Binder, IKZF1 Modulator
FC-14369 is a PROTAC degrader that selectively targets the HIV-1 Nef protein, exhibiting a DC50 value of 160 nM. By engaging both Nef and the Cereblon E3 ubiquitin ligase, FC-14369 facilitates the ubiquitination and subsequent proteasomal degradation of Nef, leading to the restoration of CD4 and MHC-I expression on the cell surface and effectively inhibiting HIV-1 replication. This compound is valuable for research focused on HIV infection and AIDS, advancing understanding of therapeutic strategies in viral infections. -
CXCR4 Antagonist
KRH-3955 hydrochloride is a potent CXCR4 antagonist that effectively inhibits the binding of SDF-1α to CXCR4 with an IC50 of 0.61 nM. This compound demonstrates strong selectivity and efficacy against X4 HIV-1, with an EC50 ranging from 0.3 to 1.0 nM. KRH-3955 hydrochloride is suitable for research applications focused on HIV-1 pathogenesis and CXCR4-related signaling pathways. -
CXCR4 Antagonist
FC131 is a potent antagonist of the CXCR4 chemokine receptor. It effectively inhibits the binding of [125I]-SDF-1 to CXCR4 with an IC50 value of 4.5 nM. Due to its mechanism of action, FC131 demonstrates significant anti-HIV activity, making it a valuable tool for research into HIV pathogenesis and potential therapeutic interventions. -
Stable Isotope
Plerixafor-d4 is a deuterated derivative of Plerixafor, a selective antagonist of the CXCR4 receptor with an IC50 of 44 nM. This compound serves as an immunostimulant and is known for its ability to mobilize hematopoietic stem cells (HSCs). Additionally, Plerixafor has demonstrated efficacy in inhibiting HIV-1 and HIV-2 replication, with an EC50 ranging from 1 to 10 nM. Plerixafor-d4 is useful in research applications requiring stable isotopes for tracking and quantification purposes. -
HIV-1 Entry Inhibitor
RPR103611 is a derivative of betulinic acid that functions as a potent HIV-1 entry inhibitor. It displays IC50 values of 80 nM for CCR5-tropic virus YU2, 0.27 nM for CXCR4-tropic virus NL4-3, and 0.17 nM for dual tropic virus 89.6. This compound is valuable for research focused on the mechanisms of HIV-1 entry and the development of antiviral therapies. -
CCR5 Antagonist
CCR5 antagonist 3 is a potent inhibitor of the CCR5 receptor, exhibiting an IC50 of 15.90 nM. This compound demonstrates broad-spectrum anti-HIV-1 activity, making it a valuable tool for research focused on HIV-1 infection mechanisms and therapeutic development. Its specificity for CCR5 enhances its potential utility in studying chemokine receptor modulation and viral entry inhibition in various biological contexts. -
CCR5 Antagonist
Ancriviroc is a small molecule CCR5 antagonist that demonstrates potent antiviral activity against various HIV-1 isolates that utilize CCR5 as an entry coreceptor, with IC50 values ranging from 0.4 to 9 nM. This compound effectively inhibits the replication of R5-utilizing HIV-1 strains in the SCID-hu Thy/Liv mice model of HIV-1 infection. Ancriviroc is a valuable tool for research focused on HIV infection and the exploration of therapeutic strategies targeting CCR5. -
CXCR4 Antagonist
CXCR4 antagonist 7 is a potent CXCR4 antagonist with an IC50 of 9.3 nM. It effectively inhibits CXCR4 receptor activity, making it a valuable tool in the investigation of HIV infection, inflammatory diseases, cancer, and WHIM syndrome. This compound provides essential insights into the roles of CXCR4 signaling in various pathological conditions. -
CCR5 Antagonist
INCB9471 is a potent and selective CCR5 antagonist that serves as a critical resource for HIV-1 research. This orally active compound effectively inhibits CCR5-mediated entry of HIV-1 into host cells, demonstrating significant anti-HIV-1 activity. Its targeted mechanism of action makes INCB9471 a valuable tool for studying HIV pathogenesis and developing therapeutic strategies against HIV infection. -
CCR5 Antagonist
Vicriviroc is a potent CCR5 antagonist with an IC50 of 10 nM. It effectively inhibits the release of MIP-1α and intracellular calcium levels induced by the ligand RANTES, with IC50 values of 0.91 nM and 16 nM, respectively. Vicriviroc is primarily utilized in research related to human immunodeficiency virus type 1 (HIV-1) infection and holds potential for cancer studies. -
CXCR Inhibitor
AMD 3329 octahydrobromide is a potent CXCR4 inhibitor that effectively reduces HIV-1 and HIV-2 viral replication. It demonstrates exceptional antiviral activity with EC50 values of 0.8 nM and 1.6 nM, surpassing the efficacy of related compounds. Additionally, AMD 3329 significantly obstructs the binding of specific CXCR4 monoclonal antibodies and inhibits SDF-1 alpha-induced Ca(2+) influx. This compound also disrupts virus-induced syncytium formation, with an EC50 of 12 nM, making it a valuable tool for HIV research and therapeutic development. -
TLR7 Agonist
TLR7 Agonist 12 is a potent TLR7 agonist and a purine nucleoside analog. This compound demonstrates significant antitumor activity, particularly against indolent lymphoid malignancies. Its anticancer mechanisms are mediated through the inhibition of DNA synthesis and the induction of apoptosis, making it valuable for research applications in cancer therapeutics and immune modulation studies. -
COX Inhibitor
Ibuprofen Impurity F is a specific impurity of Ibuprofen, a well-known anti-inflammatory compound that inhibits cyclooxygenase enzymes COX-1 and COX-2. It exhibits inhibitory activity with IC50 values of 13 μM for COX-1 and 370 μM for COX-2. This reagent is valuable for quality control and analytical characterization in pharmaceutical research and development, particularly in the study of non-steroidal anti-inflammatory drugs (NSAIDs). -
COX Inhibitor
Piroxicam cinnamate is a cyclooxygenase (COX) inhibitor with demonstrated anti-inflammatory properties. It is stable under gastric conditions, making it suitable for research applications focused on inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele-associated oligoasthenospermia. This compound offers significant potential for investigating therapeutic approaches to various inflammatory conditions. -
COX-1 Inhibitor
Valeryl salicylate is a potent and irreversible inhibitor of cyclooxygenase-1 (COX-1). This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory processes. Its mechanism offers insights into the modulation of COX-1 enzyme activity and potential therapeutic applications in inflammatory conditions. -
COX1/2 Inhibitor
4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone is a selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). This compound demonstrates significant anti-inflammatory properties and is valuable in research aimed at understanding the role of COX enzymes in various disease models. Its application extends to pharmacological studies focused on pain, inflammation, and potential therapeutic interventions. -
COX Inhibitor
Ibuprofen impurity 1 is an impurity of the widely used anti-inflammatory agent ibuprofen, which acts as a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 13 μM and 370 μM, respectively. This compound is essential for evaluating the purity and quality of ibuprofen formulations in research. It serves as a valuable tool for studying the pharmacological effects and potential side effects of ibuprofen in various biological assays. -
COX-2 Inhibitor
Robenacoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with potent anti-inflammatory and analgesic properties. It primarily reduces the production of prostaglandins associated with inflammation and pain, making it valuable for research related to inflammatory diseases and pain management. This compound is utilized in studies aiming to elucidate the role of COX-2 in various biological processes and to develop therapeutic strategies targeting inflammation. -
COX-2 Inhibitor
3-Carene is a bicyclic monoterpene that functions as a cyclooxygenase-2 (COX-2) inhibitor. It demonstrates significant anti-inflammatory properties by reducing nociceptive stimulus-induced inflammatory infiltrates and decreasing COX-2 overexpression. Additionally, 3-Carene enhances both the activity and expression of alkaline phosphatase, a crucial early marker of osteoblastic differentiation, making it a valuable compound for research in pain management and bone health. -
COX-2 Inhibitor
Mavacoxib is a selective, oral cyclooxygenase-2 (COX-2) inhibitor, functioning as a long-acting non-steroidal anti-inflammatory drug (NSAID). This compound effectively alleviates pain and inflammation related to degenerative joint disease, particularly in canine subjects. Research applications include studies on inflammation and pain management in veterinary medicine. -
COX-2 Inhibitor
Desmethyl Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 32 nM, demonstrating significant anti-inflammatory activity. As an analog of Celecoxib, this compound serves as a valuable tool in research applications focusing on inflammation and pain pathways. Its potency and specificity make it suitable for studies related to COX-2 mediated processes. -
5-LO/COX Inhibitor
BW 755C is a dual inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase (COX) enzymes, exhibiting an IC50 of 5 μM for 5-LO. It also demonstrates inhibitory activity against COX-1 and COX-2, with IC50 values of 0.65 and 1.2 μg/mL, respectively. This compound is valuable for research applications involving inflammation and other related pathways. Its ability to concurrently inhibit key lipid mediators makes BW 755C a useful tool in studies focused on arachidonic acid metabolism and signaling pathways. -
COX-2 Inhibitor
Enflicoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory pathway. This nonsteroidal anti-inflammatory compound exhibits notable anti-inflammatory, analgesic, and antipyretic effects in various animal models. Enflicoxib is valuable for research investigating COX-2-mediated processes and potential therapeutic applications in pain management and inflammation. -
COX-1 Inhibitor
CP-74006 is a selective inhibitor of Cyclooxygenase-1 (COX-1). This compound demonstrates significant anti-inflammatory activity by blocking the conversion of arachidonic acid to prostaglandins, key mediators in the inflammatory response. CP-74006 is utilized in research focusing on inflammation, pain management, and cardiovascular disease, providing valuable insights into COX-1 related biological processes. -
COX inhibitor
2-Chloro-N-(2,6-dimethylphenyl)acetamide is a cyclooxygenase (COX) inhibitor that modulates inflammatory responses by inhibiting the conversion of arachidonic acid to prostaglandins. Its biological activity makes it a valuable tool in research focused on inflammation and pain pathways. This compound is utilized for studying COX-related mechanisms in various biological contexts, potentially aiding in the development of anti-inflammatory therapies. -
COX- 2 Inhibitor
Ocarocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 1.4 μM. By inhibiting COX-2, Ocarocoxib effectively reduces the synthesis of prostaglandins, thereby imparting significant anti-inflammatory effects. This compound is useful for research on inflammation and associated pathological conditions. -
COX-2/5-LOX Inhibitor
Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases. -
COX-1 Inhibitor
Teriflunomide impurity 3, also known as 4-Amino-N-(4-trifluoromethylphenyl)benzamide, acts as a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 of 30 µM. This compound exhibits significantly lower activity against COX-2, with an IC50 greater than 100 µM. Teriflunomide impurity 3 is valuable for research applications exploring inflammatory pathways and the role of COX-1 in various biological processes. -
Non-steroidal Anti-inflammatory Agent
Bermoprofen is an orally active non-steroidal anti-inflammatory agent that primarily exerts its effects through inhibition of prostaglandin synthesis. It demonstrates significant antipyretic activity, effectively reducing fever induced by lipopolysaccharides (LPS) in animal models. Due to its rapid onset and short biological half-life, Bermoprofen is applicable in research focused on inflammatory pathways and fever response mechanisms. -
Nonsteroidal anti-inflammatory drug
(R)-Ketoprofen is an orally active nonsteroidal anti-inflammatory drug (NSAID) with potent analgesic properties. It primarily targets cyclooxygenase enzymes to inhibit prostaglandin synthesis, thereby reducing pain and inflammation. (R)-Ketoprofen has been shown to modulate inflammatory cytokine responses, without significantly enhancing the levels of tumor necrosis factor (TNF) and interleukin-1 (IL-1) induced by lipopolysaccharide (LPS). This compound is widely utilized in research applications focused on pain management and inflammatory disease pathways. -
COX
ASP6537 is a selective inhibitor of recombinant human cyclooxygenase-1 (rhCOX-1), exhibiting an IC50 value of 0.703 nM. Its potent inhibition of COX-1 makes it a valuable tool for studying the role of prostaglandins in cardiovascular disease research. Researchers can utilize ASP6537 to investigate the effects of COX-1 modulation on cardiovascular pathophysiology. -
iNOS/COX-2 Inhibitor
Rehmapicrogenin is a selective inhibitor of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). This compound, derived from the root of Rehmannia glutinosa, demonstrates significant anti-inflammatory properties, making it a valuable tool for research focused on inflammation pathways. Its ability to inhibit pro-inflammatory mediators such as IL-6 further underscores its relevance in studies aimed at understanding and treating inflammatory diseases. -
COX-1/COX-2 Inhibitor
(S)-(+)-Ibuprofen-d3 is a deuterated analog of (S)-(+)-Ibuprofen, targeting the COX-1 and COX-2 enzymes. With IC50 values of 2.1 μM and 1.6 μM, respectively, this compound exhibits significant analgesic, anti-inflammatory, and antipyretic properties. It serves as a valuable tool for studying the pharmacodynamics and mechanisms of nonsteroidal anti-inflammatory drugs (NSAIDs) in various biological research applications. -
COX Inhibitor
Isoxicam is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Its primary mechanism involves the inhibition of prostaglandin synthesis, making it effective in reducing inflammation and pain. Isoxicam is commonly utilized in research related to arthritis and other inflammatory conditions, providing valuable insights into the role of COX enzymes in various biological processes. -
COX-2 Inhibitor
Cimicoxib is a selective COX-2 inhibitor that effectively penetrates the blood-brain barrier. It displays significant anti-inflammatory, analgesic, and antipyretic properties by inhibiting the production of thromboxane B2 and prostaglandin E2, with an IC50 of 66 nM against human COX-2. Additionally, Cimicoxib targets CYP2D15, exhibiting an IC50 of 1.6 μM in canines and 0.056 μM in felines. This compound is utilized in research involving inflammatory diseases, osteoarthritis, and perioperative pain management in orthopedic and soft tissue surgeries. -
COX Inhibitor
Naproxen glucuronide, a metabolite of naproxen, functions as a non-selective cyclooxygenase (COX) inhibitor. This compound exhibits significant anti-inflammatory, analgesic, and antipyretic activity, making it useful in the study of pain relief and inflammation pathways. Research applications include examining its metabolic pathways, assessing its efficacy in various inflammatory conditions, and exploring its pharmacokinetic properties in biological systems. -
Dual COX/5-LOX Inhibitor
ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts. -
FAP Antagonist
R-75317 is a selective antagonist of platelet-activating factor (PAF). It has demonstrated the ability to prevent the decline in creatinine clearance in a rat model of antibody-induced glomerulonephritis, delay the onset of proteinuria, and ameliorate glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. This compound may serve as a valuable tool in the investigation of glomerulonephritis and related renal pathologies. -
mPGES-1 Inhibitor
Crisdesalazine is a selective inhibitor of microsomal prostaglandin E2 synthase-1 (mPGES-1). It demonstrates significant biological activity as a free radical scavenger, effectively neutralizing reactive oxygen species (ROS) such as hydrogen peroxide, thereby providing neuroprotective benefits against apoptosis and axonal damage. By inhibiting PGE2 production, Crisdesalazine also modulates inflammatory responses and facilitates the conversion of macrophages from the pro-inflammatory M1 to the anti-inflammatory M2 phenotype. This compound is particularly valuable for research focused on neuroprotection in conditions such as multiple sclerosis and spinal cord injury.
